

BSBMT CTC – IMPACT Meeting

Thursday 16th March 2017 10.30

DeVere West One, 9-10 Portland Place, Marylebone, London, W1B 1PR

Chair: Andy Peniket (BSBMT CTC)

Introduction (David Marks –IMPACT Medical Director) 10.30-10.35

Session 1. Autologous transplantation 10.35 – 11.10

IPANEMA - In vivo Purging with ANti-CD38 to Enhance Myeloma Autografting
(Chris Parrish)

Randomised comparison of R-ICE with or without durvalumab followed by autologous stem cell transplant and post-transplant maintenance with durvalumab in relapsed/ refractory diffuse large B cell lymphomas (Sridhar Chaganti)

Session 2. Sickle cell allogeneic transplantation 11.10 – 11.30

Stem cell transplant in adults with severe sickle cell disease (Victoria Potter)

Session 3. Lymphoid malignancy allogeneic transplantation 11.30 – 12.20

Phase II study of the adjuvant use of ibrutinib in patients undergoing reduced intensity conditioning allogeneic transplantation for Chronic Lymphocytic Leukaemia (CLL) and Indolent Non Hodgkin lymphoma (Panesha Shankara)

Randomised Comparison Of Fludarabine, cyclophosphamide and low dose TBI conditioning regimen with Post-Transplant Cyclophosphamide Versus Alemtuzumab Based Reduced Intensity Conditioning In Lymphoma Allografts (Ram Malladi)

Multi-centre randomized controlled study comparing fludarabine, melphalan and Campath vs cyclophosphamide (120mg/kg) plus 8 Gy of TBI as conditioning for reduced intensity allografts for patients >40 years with ALL in CR1 (David Marks)

Session 4. Supportive care 12.20 – 12.45

Evaluation of a comprehensive, rapid fungal diagnostic panel to optimise clinical management, improve patient outcomes and reduce NHS costs (Samir Agrawal)

Intravenous immunoglobulin as infection prophylaxis in allogeneic HSCT (Simon Stanworth)

LUNCH 12.45-13.15

Session 5. Acute myeloid leukaemia allogeneic transplantation 13.15 – 14.30

Phase II trial of Low dose alemtuzumab as part of the conditioning protocol in RIC Allogeneic SCT recipients for high risk AML (Emmanouil Nikolousis)

Phase I/II study of the deacetylase inhibitor pracinostat, alone or in combination with azacitidine, after allogeneic stem cell transplantation in patients with high-risk MDS or AML (Oliver Ottman)

FAST (Fast Access to Stem cell Transplantation) (Hugues de Lavallade)

FIGARO2 (Charlie Craddock)

Session 6. Donor lymphocytes, MSCs and GvHD 14.30 - 15.20

Mesenchymal stromal cells as treatment of acute GvHD in a selected cohort of patient (Francesco Dazzi)

Early Infusion of Donor Lymphocytes after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Haematological Malignancies (Eduardo Olavarria)

A Phase II Prospective Trial of Prophylactic Donor Lymphocyte Infusions for the Prevention of Relapse post HSCT in patients with High Risk Myeloid Malignancy (Victoria Potter)

Efficacy of extracorporeal photopheresis (ECP) with ultraviolet A activated 8-methoxypsoralen as first-line immunotherapy for acute graft versus host disease (ECP-First) (Amit Patel)

Session 7. Conditioning and Donor Selection 15.30 – 16.10

Multi-centre randomized controlled study comparing alemtuzumab versus post-transplant cyclophosphamide as graft-versus-host disease prophylaxis following matched unrelated donor stem cell transplantation (Ronjon Chakraverty)

Efficacy and safety of haplo-identical or cord blood donor allogeneic stem cell transplantation compared to a mismatched unrelated donor (DONOR trial) (Amit Patel)